AstraZeneca PLC (AZN) Q2 FY2026 Financial Statements: Revenue $15.38B, Net income $2.51B
More for AstraZeneca: Company index · 20-F and 6-K summary · 6-K filings and events
PeriodQ2 FY2026
Published
AstraZeneca reported total revenue of $15.38 billion for Q2 FY2026, the quarter ended June 30, 2026, up 6.4% from a year earlier, and net income attributable to shareholders of $2.51 billion, up 2.3%, or $1.61 per diluted ordinary share. Operating profit was $3.16 billion, down 9.8%, because of larger charges that AstraZeneca excludes from its Core measures, mainly intangible amortisation and impairments, including write-downs of development-stage intangible assets in research and development, but a lower tax charge more than offset that decline at the net income line. On its Core basis, which also excludes restructuring costs and other listed items, costs grew roughly in line with revenue, Core operating profit rose and AstraZeneca earned $2.63 per share.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $15,384,000,000 | up 6.4% |
| Net income | $2,507,000,000 | up 2.3% |
| Diluted EPS | $1.61 | up 2.5% |
| Operating profit | $3,164,000,000 | down 9.8% |
| Core EPS | $2.63 |
Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. Figures calculated here, such as margins, free cash flow and trailing-twelve-month totals, have no line in a filing to point to and are not linked.
About this file
| Ticker | AZN |
|---|---|
| CIK | 0000901832 |
| Company | AstraZeneca PLC |
| Business type | pharmaceutical |
| Schema template | standard (industrial/pharma): revenue split into Product Sales, Alliance Revenue and Collaboration Revenue as AstraZeneca presents it; IFRS line names |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual US dollars (not millions); per-share figures in US dollars per ordinary share; share counts in actual shares |
AZN annual income statement, balance sheet and cash flow
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Period start | 2025-01-01 | 2024-01-01 | 2023-01-01 |
| Period end | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 20-F | 20-F | 20-F |
| Income statement | |||
| Product sales | 55,573,000,000 | 50,938,000,000 | 43,789,000,000 |
| Alliance revenue | 3,067,000,000 | 2,212,000,000 | 1,428,000,000 |
| Product revenue | 58,640,000,000 | 53,150,000,000 | 45,217,000,000 |
| Collaboration revenue | 99,000,000 | 923,000,000 | 594,000,000 |
| Total revenue | 58,739,000,000 | 54,073,000,000 | 45,811,000,000 |
| Cost of sales | 10,633,000,000 | 10,207,000,000 | 8,268,000,000 |
| Gross profit | 48,106,000,000 | 43,866,000,000 | 37,543,000,000 |
| Distribution expense | 579,000,000 | 555,000,000 | 539,000,000 |
| Research and development expense | 14,232,000,000 | 13,583,000,000 | 10,935,000,000 |
| Selling general and administrative expense | 19,933,000,000 | 19,977,000,000 | 19,216,000,000 |
| Other operating income and expense | 381,000,000 | 252,000,000 | 1,340,000,000 |
| Operating profit | 13,743,000,000 | 10,003,000,000 | 8,193,000,000 |
| Finance income | 360,000,000 | 458,000,000 | 344,000,000 |
| Finance expense | 1,694,000,000 | 1,742,000,000 | 1,626,000,000 |
| Share of losses of associates and joint ventures | 7,000,000 | 28,000,000 | 12,000,000 |
| Profit before tax | 12,402,000,000 | 8,691,000,000 | 6,899,000,000 |
| Taxation | 2,169,000,000 | 1,650,000,000 | 938,000,000 |
| Net income | 10,233,000,000 | 7,041,000,000 | 5,961,000,000 |
| Net income attributable to owners of parent | 10,225,000,000 | 7,035,000,000 | 5,955,000,000 |
| Net income attributable to noncontrolling interests | 8,000,000 | 6,000,000 | 6,000,000 |
| Basic EPS | 6.60 | 4.54 | 3.84 |
| Diluted EPS | 6.54 | 4.50 | 3.81 |
| Basic shares | 1,550,000,000 | 1,550,000,000 | 1,549,000,000 |
| Diluted shares | 1,562,000,000 | 1,563,000,000 | 1,562,000,000 |
| Balance sheet | |||
| Property plant and equipment | 12,962,000,000 | 10,252,000,000 | |
| Goodwill | 21,242,000,000 | 21,025,000,000 | |
| Intangible assets | 37,846,000,000 | 37,177,000,000 | |
| Total non current assets | 85,351,000,000 | 78,208,000,000 | |
| Inventories | 6,557,000,000 | 5,288,000,000 | |
| Trade and other receivables | 15,177,000,000 | 12,972,000,000 | |
| Cash and cash equivalents | 5,711,000,000 | 5,488,000,000 | |
| Total current assets | 28,723,000,000 | 25,827,000,000 | |
| Total assets | 114,074,000,000 | 104,035,000,000 | |
| Current interest bearing loans and borrowings | 3,104,000,000 | 2,337,000,000 | |
| Current lease liabilities | 382,000,000 | 339,000,000 | |
| Trade and other payables | 25,280,000,000 | 22,465,000,000 | |
| Total current liabilities | 30,617,000,000 | 27,866,000,000 | |
| Non current interest bearing loans and borrowings | 24,715,000,000 | 26,506,000,000 | |
| Non current lease liabilities | 1,421,000,000 | 1,113,000,000 | |
| Total non current liabilities | 34,738,000,000 | 35,298,000,000 | |
| Total liabilities | 65,355,000,000 | 63,164,000,000 | |
| Equity attributable to owners of parent | 48,667,000,000 | 40,786,000,000 | |
| Noncontrolling interests | 52,000,000 | 85,000,000 | |
| Total equity | 48,719,000,000 | 40,871,000,000 | |
| Total debt | 27,819,000,000 | 28,843,000,000 | |
| Cash flow | |||
| Depreciation amortisation and impairment | 5,733,000,000 | 6,688,000,000 | 5,387,000,000 |
| Operating cash flow | 14,575,000,000 | 11,861,000,000 | 10,345,000,000 |
| Acquisition of subsidiaries net of cash acquired | -66,000,000 | -2,771,000,000 | -189,000,000 |
| Capex | -2,810,000,000 | -1,924,000,000 | -1,361,000,000 |
| Purchase of intangible assets | -3,095,000,000 | -2,662,000,000 | -2,417,000,000 |
| Investing cash flow | -6,808,000,000 | -7,980,000,000 | -4,064,000,000 |
| Dividends paid | -4,971,000,000 | -4,629,000,000 | -4,481,000,000 |
| Financing cash flow | -7,544,000,000 | -3,996,000,000 | -6,567,000,000 |
| Cash and cash equivalents at end of period net of overdrafts | 5,698,000,000 | 5,429,000,000 | 5,637,000,000 |
| Free cash flow | 11,765,000,000 | 9,937,000,000 | 8,984,000,000 |
AZN quarterly income statement, balance sheet and cash flow
| Q2 2026 | Q2 2025 | |
|---|---|---|
| Period start | 2026-04-01 | 2025-04-01 |
| Period end | 2026-06-30 | 2025-06-30 |
| Period type | three months | three months |
| Source accession | 6-K | 6-K |
| Income statement | ||
| Product sales | 14,510,000,000 | 13,795,000,000 |
| Alliance revenue | 874,000,000 | 654,000,000 |
| Product revenue | 15,384,000,000 | 14,449,000,000 |
| Total revenue | 15,384,000,000 | 14,457,000,000 |
| Cost of sales | 2,523,000,000 | 2,473,000,000 |
| Gross profit | 12,861,000,000 | 11,984,000,000 |
| Distribution expense | 145,000,000 | 143,000,000 |
| Research and development expense | 4,053,000,000 | 3,548,000,000 |
| Selling general and administrative expense | 5,651,000,000 | 4,864,000,000 |
| Other operating income and expense | 152,000,000 | 79,000,000 |
| Operating profit | 3,164,000,000 | 3,508,000,000 |
| Finance income | 80,000,000 | 68,000,000 |
| Finance expense | 435,000,000 | 439,000,000 |
| Share of losses of associates and joint ventures | 10,000,000 | 10,000,000 |
| Profit before tax | 2,799,000,000 | 3,127,000,000 |
| Taxation | 291,000,000 | 679,000,000 |
| Net income | 2,508,000,000 | 2,448,000,000 |
| Net income attributable to owners of parent | 2,507,000,000 | 2,450,000,000 |
| Net income attributable to noncontrolling interests | 1,000,000 | -2,000,000 |
| Basic EPS | 1.61 | 1.58 |
| Diluted EPS | 1.61 | 1.57 |
| Basic shares | 1,551,000,000 | 1,550,000,000 |
| Diluted shares | 1,560,000,000 | 1,559,000,000 |
| Collaboration revenue | 0 | 8,000,000 |
| Balance sheet | ||
| Property plant and equipment | 13,615,000,000 | 11,637,000,000 |
| Goodwill | 21,181,000,000 | 21,222,000,000 |
| Intangible assets | 37,723,000,000 | 37,925,000,000 |
| Total non current assets | 87,868,000,000 | 83,483,000,000 |
| Inventories | 6,932,000,000 | 6,467,000,000 |
| Trade and other receivables | 14,330,000,000 | 14,168,000,000 |
| Cash and cash equivalents | 4,893,000,000 | 7,058,000,000 |
| Total current assets | 27,965,000,000 | 28,939,000,000 |
| Total assets | 115,833,000,000 | 112,422,000,000 |
| Current interest bearing loans and borrowings | 5,808,000,000 | 6,492,000,000 |
| Current lease liabilities | 426,000,000 | 361,000,000 |
| Trade and other payables | 22,893,000,000 | 23,986,000,000 |
| Total current liabilities | 31,553,000,000 | 33,536,000,000 |
| Non current interest bearing loans and borrowings | 23,683,000,000 | 24,714,000,000 |
| Non current lease liabilities | 2,322,000,000 | 1,272,000,000 |
| Total non current liabilities | 33,910,000,000 | 34,076,000,000 |
| Total liabilities | 65,463,000,000 | 67,612,000,000 |
| Equity attributable to owners of parent | 50,295,000,000 | 44,719,000,000 |
| Noncontrolling interests | 75,000,000 | 91,000,000 |
| Total equity | 50,370,000,000 | 44,810,000,000 |
| Net debt | 26,912,000,000 | 25,227,000,000 |
| Total debt | 29,491,000,000 | 31,206,000,000 |
| Non GAAP | ||
| Core operating profit | 5,158,000,000 | |
| Core EPS | 2.63 | |
AZN year-to-date income statement and cash flow
| H1 2026 | H1 2025 | |
|---|---|---|
| Period start | 2026-01-01 | 2025-01-01 |
| Period end | 2026-06-30 | 2025-06-30 |
| Period type | six months | six months |
| Source accession | 6-K | 6-K |
| Income statement | ||
| Product sales | 28,896,000,000 | 26,670,000,000 |
| Alliance revenue | 1,699,000,000 | 1,293,000,000 |
| Product revenue | 30,595,000,000 | 27,963,000,000 |
| Collaboration revenue | 77,000,000 | 82,000,000 |
| Total revenue | 30,672,000,000 | 28,045,000,000 |
| Cost of sales | 5,201,000,000 | 4,714,000,000 |
| Gross profit | 25,471,000,000 | 23,331,000,000 |
| Distribution expense | 286,000,000 | 278,000,000 |
| Research and development expense | 7,545,000,000 | 6,707,000,000 |
| Selling general and administrative expense | 10,571,000,000 | 9,356,000,000 |
| Other operating income and expense | 341,000,000 | 192,000,000 |
| Operating profit | 7,410,000,000 | 7,182,000,000 |
| Finance income | 153,000,000 | 149,000,000 |
| Finance expense | 828,000,000 | 785,000,000 |
| Share of losses of associates and joint ventures | 22,000,000 | 17,000,000 |
| Profit before tax | 6,713,000,000 | 6,529,000,000 |
| Taxation | 1,124,000,000 | 1,160,000,000 |
| Net income | 5,589,000,000 | 5,369,000,000 |
| Net income attributable to owners of parent | 5,587,000,000 | 5,366,000,000 |
| Net income attributable to noncontrolling interests | 2,000,000 | 3,000,000 |
| Basic EPS | 3.60 | 3.46 |
| Diluted EPS | 3.58 | 3.44 |
| Basic shares | 1,550,000,000 | 1,550,000,000 |
| Diluted shares | 1,561,000,000 | 1,560,000,000 |
| Cash flow | ||
| Depreciation amortisation and impairment | 3,295,000,000 | 2,673,000,000 |
| Operating cash flow | 6,224,000,000 | 7,099,000,000 |
| Capex | -1,310,000,000 | -1,088,000,000 |
| Purchase of intangible assets | -3,333,000,000 | -1,804,000,000 |
| Investing cash flow | -4,704,000,000 | -3,361,000,000 |
| Dividends paid | -3,288,000,000 | -3,357,000,000 |
| Financing cash flow | -2,325,000,000 | -2,189,000,000 |
| Cash and cash equivalents at end of period net of overdrafts | 4,884,000,000 | 7,032,000,000 |
| Free cash flow | 4,914,000,000 | 6,011,000,000 |
| Non GAAP | ||
| Core operating profit | 10,510,000,000 | |
| Core EPS | 5.21 | |
| Dividends | ||
| Interim dividend declared per share | 1.06 | |
AZN trailing twelve month income statement and cash flow
| Twelve months ended 30 June 2026 | |
|---|---|
| Period start | 2025-07-01 |
| Period end | 2026-06-30 |
| Period type | trailing twelve months |
| Source accession | 6-K |
| Source accessions | 20-F, 6-K |
| Income statement | |
| Product sales | 57,799,000,000 |
| Alliance revenue | 3,473,000,000 |
| Product revenue | 61,272,000,000 |
| Collaboration revenue | 94,000,000 |
| Total revenue | 61,366,000,000 |
| Cost of sales | 11,120,000,000 |
| Gross profit | 50,246,000,000 |
| Distribution expense | 587,000,000 |
| Research and development expense | 15,070,000,000 |
| Selling general and administrative expense | 21,148,000,000 |
| Other operating income and expense | 530,000,000 |
| Operating profit | 13,971,000,000 |
| Profit before tax | 12,586,000,000 |
| Taxation | 2,133,000,000 |
| Net income | 10,453,000,000 |
| Net income attributable to owners of parent | 10,446,000,000 |
| Diluted EPS | 6.68 |
| Cash flow | |
| Operating cash flow | 13,700,000,000 |
| Capex | -3,032,000,000 |
| Purchase of intangible assets | -4,624,000,000 |
| Dividends paid | -4,902,000,000 |
| Free cash flow | 10,668,000,000 |
Adjustments
| Splits applied | none |
|---|---|
| ADR ratio | n/a |
| FX | none: AstraZeneca presents its consolidated statements in US dollars, its functional currency |
| Per share basis | per Ordinary Share of $0.25 nominal value. AstraZeneca terminated its American Depositary Receipt programme and listed its Ordinary Shares directly on the New York Stock Exchange effective 2 February 2026, so a US holder now owns Ordinary Shares and no ADS conversion applies. |
| Sign convention | income statement expense lines (cost of sales, distribution, R&D, SG&A, finance expense, share of associate and joint venture losses, taxation) are stored as positive amounts; other operating income and expense is net income (positive) or net expense (negative); balance sheet liabilities, borrowings and net debt are stored as positive amounts; cash flow lines keep the statement's sign (outflows negative). |
Notes
- Template: a standard industrial/pharmaceutical layout using AstraZeneca's own IFRS line names. Total Revenue is Product Revenue (Product Sales plus Alliance Revenue) plus Collaboration Revenue, as the company presents it; Operating profit is the IFRS 'Operating profit' line; net_income is 'Profit for the period' and net_income_attributable_to_owners_of_parent is the earnings-per-share numerator.
- Annual figures for FY2023, FY2024 and FY2025 come from the FY2025 Form 20-F (accession 0001104659-26-019130). The 20-F prints three years of income statement and cash flows and two year-ends of balance sheet, so FY2023 carries no balance sheet.
- Q2 2026, Q2 2025, H1 2026 and H1 2025 come from the H1 and Q2 2026 results furnished on Form 6-K on 27 July 2026 (accession 0001104659-26-086846). AstraZeneca files no Form 10-Q; its interim statements are furnished on Form 6-K.
- The quarterly entries carry no cash flow statement: the interim results print cash flows for the half year only (H1 2026 and H1 2025), and no first-quarter 2026 cash flow statement is among the filings for this period, so the second quarter's cash flows cannot be derived. Half-year cash flows are in the year-to-date block.
- The Q2 2026 and Q2 2025 three-month income statements are labelled 'Unreviewed' in the filing; the half-year statements were reviewed by the auditors under ISRE 2410.
- Q2 2026 Collaboration Revenue is printed as a dash (nil); Total Revenue equals Product Revenue of $15,384m in that quarter.
- total_debt is interest-bearing loans and borrowings, current plus non-current, as printed on the statement of financial position; it excludes lease liabilities, which are shown separately. net_debt is AstraZeneca's own non-GAAP measure from its Net debt summary (gross borrowings including leases, net of derivatives, less cash and current investments) and is given for 30 June 2026 and 30 June 2025.
- capex is 'Purchase of property, plant and equipment'. free_cash_flow is net cash inflow from operating activities less that capex. It does not deduct 'Purchase of intangible assets' (licences, milestones and software), which is shown separately and was $3,333m in H1 2026 against $1,804m in H1 2025, including a $1,104m upfront payment to CSPC Pharmaceuticals. AstraZeneca's own capital expenditure measure, which adds software-related intangibles, was $1,513m in H1 2026 (H1 2025: $1,303m).
- The trailing twelve months to 30 June 2026 are derived as FY2025 (from the FY2025 Form 20-F (accession 0001104659-26-019130)) plus H1 2026 less H1 2025 (both from the H1 and Q2 2026 results furnished on Form 6-K on 27 July 2026 (accession 0001104659-26-086846)). Its diluted EPS of $6.68 is the same sum applied to the printed per-share figures, not a figure the company reports.
- non_gaap holds AstraZeneca's Core measures (Core operating profit and Core EPS) from its reconciliation tables (Tables 10 and 11). Core figures exclude restructuring costs, intangible asset amortisation and impairments, and other items the company lists; they are company-defined and not IFRS measures. The filing prints the current-period Core figures and their percentage change, not the prior-year Core amounts.
- The H1 2026 interim dividend declared is $1.06 per Ordinary Share, announced with the results on 27 July 2026 and paid on 8 September 2026; the company says it intends to increase the FY2026 annual dividend to $3.30 per share.
- Share data: AstraZeneca did not split or consolidate its shares in these periods; the weighted average share count is about 1,550 million throughout and no per-share figure has been adjusted. On 2 February 2026 its ADR programme ended and its Ordinary Shares began trading directly on the New York Stock Exchange, so every per-share figure here, before and after that date, is per Ordinary Share.
- The H1 2025 and Q2 2025 comparatives for Total Revenue, profit for the period and diluted EPS are unchanged from those AstraZeneca reported in its H1 2025 results, and the 31 December 2025 balance sheet totals in the interim results (total assets $114,074m, total liabilities $65,355m, total equity $48,719m) are the same as in the FY2025 Form 20-F.
Uncertainties
- Second-quarter cash flows (operating cash flow, capex, free cash flow) are not available for Q2 2026 or Q2 2025, because the interim results print only half-year cash flows.
- The trailing-twelve-month diluted EPS ($6.68) is a sum of reported per-share amounts, not earnings divided by a weighted share count, and may differ by a cent or two from a figure computed on a twelve-month share count.
Company details
| Name | Astrazeneca Plc |
|---|---|
| Ticker | AZN |
| CIK | 0000901832 |
| Exchange | NYSE |
| State | |
| Incorporation | United Kingdom |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
Fiscal period
| Fiscal year | 2026 |
|---|---|
| Fiscal period | Q2 |
| Tag | FY26Q2 |
| Period end | 2026-06-30 |
| Form | 6-K |
| Accession | 0001104659-26-086846 |
| Fiscal year end | 1231 |
| Source | derived |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Source |
|---|---|---|---|---|---|---|---|---|---|
| annual | no | 20-F | 2025 | FY | FY25 | 2025-12-31 | 2026-02-24 | 0001104659-26-019130 | reported |
| quarterly | yes | 6-K | 2026 | Q2 | FY26Q2 | 2026-06-30 | 2026-07-27 | 0001104659-26-086846 | derived |
FAQ · AstraZeneca financial statements
How much revenue did AstraZeneca make in Q2 FY2026?
AstraZeneca reported total revenue of $15.38 billion for Q2 FY2026, the quarter ended June 30, 2026. That is up 6.4% from $14.46 billion in the same quarter a year earlier.
What were AstraZeneca's net income and EPS in Q2 FY2026?
AstraZeneca's net income attributable to shareholders was $2.51 billion in Q2 FY2026, up 2.3% from $2.45 billion a year earlier. Diluted earnings per ordinary share were $1.61, against $1.57 in the same quarter a year earlier.
Why did AstraZeneca's operating profit fall in Q2 FY2026?
AstraZeneca's operating profit was $3.16 billion in Q2 FY2026, down 9.8% from $3.51 billion a year earlier, because of larger charges that AstraZeneca excludes from its Core measures: impairments of development-stage intangible assets in research and development, and intangible amortisation and impairments, restructuring and other listed items in selling, general and administrative costs. On its Core basis, costs grew roughly in line with revenue and Core operating profit rose. Despite the lower reported operating profit, a lower tax charge, which reflected an adjustment to deferred tax assets, meant AstraZeneca's net income still rose to $2.51 billion.
What was AstraZeneca's Core EPS in Q2 FY2026?
AstraZeneca reported Core earnings per share of $2.63 for Q2 FY2026, the quarter ended June 30, 2026. Core EPS is the company's own measure, not an IFRS figure; it excludes intangible amortisation and impairments, restructuring costs and other items the company lists, and compares with reported diluted EPS of $1.61.
Where can I get AstraZeneca PLC (AZN) financial data in machine-readable form?
Ticker Scout publishes AstraZeneca PLC's financial statements as JSON at https://tickerscout.ai/azn/financials.json, free, with no API key and no signup. The 20-F and 6-K narrative and the 6-K events digest are published as Markdown at https://tickerscout.ai/azn/narrative.md and https://tickerscout.ai/azn/events.md. AstraZeneca PLC's SEC CIK is 0000901832. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does AstraZeneca PLC (AZN) next file with the SEC?
AstraZeneca PLC (AZN) is expected to file its next Form 6-K with the SEC on or around November 5, 2026. That date is a projection rather than a company-announced date: it is derived from AstraZeneca PLC's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 6-K for Q2 FY2026, the period ended 2026-06-30, SEC accession 0001104659-26-086846.
Related companies
How this page was built
This page was built from two of AstraZeneca PLC's own filings with the SEC, read one at a time. Nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names two such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from AstraZeneca PLC's SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.